Keyphrases
Brain Atrophy
100%
Multiple Sclerosis
100%
Heterogeneous Treatment Effects
100%
Two-stage Model
100%
Disease-modifying Therapy
85%
Brain Parenchymal Fraction
85%
Brain MRI
42%
Fraction Change
42%
Natalizumab
28%
Model Performance
28%
Linear Mixed Model
28%
Propensity Score Weighting
28%
Interferon-α (IFN-α)
14%
Risk Model
14%
Between-group
14%
Poor Outcome
14%
Personalized Medicine
14%
Objective Outcome Measure
14%
Siemens
14%
Treatment Effect
14%
Method Analysis
14%
Baseline Data
14%
Treatment Duration
14%
Rituximab
14%
Therapy Efficacy
14%
Sensitivity Analysis
14%
Baseline Covariates
14%
Therapy Selection
14%
Pathological Changes
14%
Relative Benefit
14%
Advanced Technologies
14%
Alemtuzumab
14%
Baseline Risk
14%
High Efficacy
14%
Fingolimod
14%
Glatiramer Acetate
14%
Standardized Mean Difference
14%
Cladribine
14%
Ocrelizumab
14%
Change Risk
14%
Dimethyl Fumarate
14%
Technology Solutions
14%
Teriflunomide
14%
Healthcare Solutions
14%
Acquisition Sequences
14%
Solution Network
14%
Treatment Effect Model
14%
Pseudoatrophy
14%
Medicine and Dentistry
Cerebral Atrophy
100%
Multiple Sclerosis
100%
Treatment Effect
100%
Disease Modifying Therapy
85%
Magnetic Resonance Imaging of Brain
42%
Natalizumab
28%
Interferon
14%
Magnetic Resonance Imaging
14%
Combination Therapy
14%
Personalized Medicine
14%
Rituximab
14%
Alemtuzumab
14%
Glatiramer
14%
Fingolimod
14%
Cladribine
14%
Teriflunomide
14%
Fumaric Acid Dimethyl Ester
14%
Ocrelizumab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Brain Atrophy
100%
Diseases
85%
Natalizumab
28%
Combination Therapy
14%
Interferon
14%
Rituximab
14%
Fingolimod
14%
Glatiramer
14%
Alemtuzumab
14%
Cladribine
14%
Ocrelizumab
14%
Fumaric Acid Dimethyl Ester
14%
Teriflunomide
14%
Neuroscience
Multiple Sclerosis
100%
Magnetic Resonance Imaging of Brain
60%
Natalizumab
40%
Magnetic Resonance Imaging
20%
Interferon
20%
Rituximab
20%
Glatiramer Acetate
20%
Alemtuzumab
20%
Ocrelizumab
20%
Cladribine
20%
Teriflunomide
20%
Fingolimod
20%
Psychology
Magnetic Resonance Imaging
100%
Standardized Mean Difference
25%